These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12430546)

  • 21. Motion sickness and its prevention by drugs.
    Brand JJ
    Curr Med Drugs; 1967 Aug; 7(12):17-26. PubMed ID: 6064966
    [No Abstract]   [Full Text] [Related]  

  • 22. Appropriateness of kaolin consumption as an index of motion sickness in the rat.
    McCaffrey RJ
    Physiol Behav; 1985 Aug; 35(2):151-6. PubMed ID: 4070378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Space motion sickness medications: interference with biomedical parameters.
    Vernikos-Danellis J; Winget CM; Leach CS; Rosenblatt LS; Lyman J; Beljan JR
    Acta Astronaut; 1977; 4(11-12):1159-69. PubMed ID: 11829024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modafinil as a potential motion sickness countermeasure.
    Hoyt RE; Lawson BD; McGee HA; Strompolis ML; McClellan MA
    Aviat Space Environ Med; 2009 Aug; 80(8):709-15. PubMed ID: 19653573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacologic agents for preventing and treating motion sickness].
    Shashkov VS; Sabaev VV
    Kosm Biol Aviakosm Med; 1981; 15(1):9-18. PubMed ID: 6111621
    [No Abstract]   [Full Text] [Related]  

  • 26. Investigation of anti-motion sickness drugs in the squirrel monkey.
    Cheung BS; Money KE; Kohl RL; Kinter LB
    J Clin Pharmacol; 1992 Feb; 32(2):163-75. PubMed ID: 1613127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pica as an index of motion sickness in rats.
    Morita M; Takeda N; Kubo T; Matsunaga T
    ORL J Otorhinolaryngol Relat Spec; 1988; 50(3):188-92. PubMed ID: 3261413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coping with space motion sickness in Spacelab missions.
    Graybiel A
    Acta Astronaut; 1981; 8(9-10):1015-8. PubMed ID: 11543090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparative in-flight study of a scopolamine-containing membrane plaster versus dimenhydrinate under defined acceleration conditions].
    Offenloch K; Zahner G; Dietlein G; Franz I
    Arzneimittelforschung; 1986 Sep; 36(9):1401-6. PubMed ID: 3539128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuropharmacological mechanisms of emesis. I. Effects of antiemetic drugs on motion- and apomorphine-induced pica in rats.
    Takeda N; Hasegawa S; Morita M; Horii A; Uno A; Yamatodani A; Matsunaga T
    Methods Find Exp Clin Pharmacol; 1995 Nov; 17(9):589-90. PubMed ID: 8786672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Scutellaria baicalensis extract decreases cisplatin-induced pica in rats.
    Aung HH; Dey L; Mehendale S; Xie JT; Wu JA; Yuan CS
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):453-8. PubMed ID: 12942313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prevention of motion sickness with a transdermal therapeutic system containing scopolamine. A randomized, comparative double-blind study in the German Federal Navy].
    Becker G; Goossens H; Seemann K; Souchon F; Weitz T
    Dtsch Med Wochenschr; 1984 Dec; 109(49):1881-5. PubMed ID: 6499689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Motion sickness in cats: a symptom rating scale used in laboratory and flight tests.
    Suri KB; Crampton GH; Daunton NG
    Aviat Space Environ Med; 1979 Jun; 50(6):614-8. PubMed ID: 475712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of antimotion sickness drugs.
    Wood CD; Manno JE; Wood MJ; Manno BR; Redetzki HM
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A262-5. PubMed ID: 3675502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of treatment strategies for Space Motion Sickness.
    Davis JR; Jennings RT; Beck BG
    Microgravity Q; 1992 Jul; 2(3):173-7. PubMed ID: 11541442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Motion sickness-induced pica in the rat.
    Mitchell D; Laycock JD; Stephens WF
    Am J Clin Nutr; 1977 Feb; 30(2):147-50. PubMed ID: 556878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of some effects of three antimotion sickness drugs on nystagmic responses to angular accelerations and to optokinetic stimuli.
    Collins WE; Schroeder DJ; Elam GW
    Aviat Space Environ Med; 1982 Dec; 53(12):1182-9. PubMed ID: 7159338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Motion sickness and its treatment (author's transl)].
    Petrin A
    Schweiz Rundsch Med Prax; 1974 Jan; 63(3):79-81. PubMed ID: 4153225
    [No Abstract]   [Full Text] [Related]  

  • 39. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z; Shupak A; Gordon CR
    Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vestibular evoked myogenic potentials and motion sickness medications.
    Tal D; Shemy S; Kaminski-Graif G; Wiener G; Hershkovitz D
    Clin Neurophysiol; 2016 Jun; 127(6):2350-4. PubMed ID: 27178852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.